OncoMatch/Clinical Trials/NCT06235203
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Is NCT06235203 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Neoadjuvant therapy,Toripalimab and Adjuvant therapy in experimental group,Toripalimab for recurrent nasopharyngeal carcinoma.
Treatment: Neoadjuvant therapy,Toripalimab · Adjuvant therapy in experimental group,Toripalimab — A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT2, RT3, RT4
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — definitive
≥6months from the accomplishment of radical radiation to recurrence
Cannot have received: radiation therapy
Exception: previously only 1 course of radiotherapy
previously only 1 course of radiotherapy
Cannot have received: radioactive particle implantation
History of radioactive particle planting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify